Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
This DPP-4 inhibitor is contraindicated in this patient group on the basis of the respective cardiovascular safety study that has shown a significant increase of hospitalization for heart failure as secondary endpoint in the saxagliptin arm (63, 66)
KPV's anti-inflammatory contribution is relevant here: synovial inflammation is a consistent feature of chronic joint stress models, and the reduction of IL-1 and TNF- that KPV demonstrates in cell culture models would be a logical correlate in a joint-stress research context [7]
Intraoperative awareness risk, anesthetic sensitivity, and anesthetic management for patients with natural red hair: a matched cohort study
CASTLE-AF Steering Committee
Chang et al., 2024)
